Statements (79)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:academic_advisor |
leading experts
|
| gptkbp:advances |
new methodologies
state-of-the-art equipment |
| gptkbp:analysis |
bioinformatics
|
| gptkbp:awards |
biotechnology innovation awards
|
| gptkbp:biotech_ecosystem |
thriving environment
|
| gptkbp:biotech_research |
innovative projects
|
| gptkbp:ceo |
gptkb:David_E._Smith
|
| gptkbp:client_base |
academic and commercial entities
|
| gptkbp:clinical_trial |
ongoing studies
improving diagnostics |
| gptkbp:collaborates_with |
gptkb:NHS
|
| gptkbp:collaboration |
pharmaceutical companies
international research projects |
| gptkbp:collaborations |
interdisciplinary studies
academic partnerships |
| gptkbp:collaborative_projects |
multi-disciplinary teams
|
| gptkbp:community |
active participation
|
| gptkbp:community_engagement |
local initiatives
|
| gptkbp:community_outreach |
educational initiatives
|
| gptkbp:community_support |
local partnerships
|
| gptkbp:conference |
biotechnology conferences
|
| gptkbp:contribution |
personalized medicine
advancing knowledge in epigenetics |
| gptkbp:customer_support |
dedicated team
|
| gptkbp:development |
cutting-edge research
|
| gptkbp:focus |
cancer research
|
| gptkbp:founded |
gptkb:2012
|
| gptkbp:founder |
gptkb:Shankar_Balasubramanian
|
| gptkbp:funding |
gptkb:venture_capital
private investors |
| gptkbp:future_goals |
expanding research capabilities
leading in epigenetic solutions |
| gptkbp:goal |
advancing epigenetic research
|
| gptkbp:grants |
government funding
|
| gptkbp:headquarters |
gptkb:Cambridge,_UK
|
| gptkbp:healthcare |
personalized therapies
|
| https://www.w3.org/2000/01/rdf-schema#label |
Cambridge Epigenetix
|
| gptkbp:impact |
healthcare
improving patient outcomes |
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:initiatives |
global health challenges
|
| gptkbp:innovation |
research and development
genomic technologies breakthrough discoveries novel approaches |
| gptkbp:invention |
epigenetic methods
|
| gptkbp:investment |
biotech funding rounds
|
| gptkbp:involved_technology |
biomedical research
|
| gptkbp:is_a_platform_for |
next-generation sequencing
|
| gptkbp:leadership |
industry leaders
experienced professionals |
| gptkbp:market |
genomics
|
| gptkbp:market_position |
leading epigenetics company
|
| gptkbp:network |
biotech community
|
| gptkbp:partnership |
various academic institutions
|
| gptkbp:partnerships |
global organizations
|
| gptkbp:product |
new technologies
epigenetic sequencing technology |
| gptkbp:publications |
gptkb:academic_journals
|
| gptkbp:reach |
international collaborations
|
| gptkbp:regulatory_compliance |
healthcare regulations
|
| gptkbp:research |
biomarkers
cutting-edge studies |
| gptkbp:research_areas |
molecular biology
|
| gptkbp:research_focus |
epigenetic modifications
|
| gptkbp:security |
high standards
|
| gptkbp:services |
genomic analysis
|
| gptkbp:specializes_in |
epigenetics
|
| gptkbp:sustainability |
ethical research practices
|
| gptkbp:team |
scientists and engineers
|
| gptkbp:technology |
DNA methylation analysis
|
| gptkbp:trends |
epigenetic research advancements
|
| gptkbp:uses_technology |
clinical applications
|
| gptkbp:vision |
transforming healthcare through epigenetics
|
| gptkbp:website |
www.cambridgeepigenetix.com
|
| gptkbp:bfsParent |
gptkb:Cambridge_Cluster
|
| gptkbp:bfsLayer |
6
|